Prior research, including our investigations, has demonstrated that CB2 specific agonists possess therapeutic potential in the treatment of collagen-induced arthritis (CIA) and systemic sclerosis (SSc) through the modulation of T cell-mediated immune responses and the restoration of immune equilibrium (Gui et al., 2014; Tian et al., 2024). Here, CNR2 is linked to systemic sclerosis.